Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.87 |
| ▸ | EGFR | P00533 | 20/20 | 0.87 |
| ▸ | ABL2 | P42684 | 20/20 | 0.87 |
| ▸ | SRC | P12931 | 17/20 | 0.87 |
| ▸ | LCK | P06239 | 5/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016766 | 0.93 | ABL1 (1.00) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL7020345 | 0.92 | ABL1 (1.00) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL7018115 | 0.91 | ABL1 (1.00) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL7021384 | 0.88 | EGFR (1.00) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL7014326 | 0.88 | ABL1 (0.86) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL7023792 | 0.87 | ABL1 (1.00) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL7019158 | 0.87 | ABL1 (0.74) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL8107295 | 0.86 | EGFR (0.86) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL12856462 | 0.84 | EGFR (1.00) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL7014659 | 0.84 | ABL1 (0.72) | ABL1EGFRABL2SRCLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888353-B1 | N-7-HETEROCYCLYL PYRROLO [2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2003-07-09 | — | — | EP | claimed |
| EP-0888353-B1 | N-7-HETEROCYCLYL PYRROLO [2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-6051577-A | TYROSINE INHIBITORS; BONE DISORDERS | NOVARTIS AG (CH) | 2000-04-18 | — | — | US | disclosed |